...
首页> 外文期刊>Journal of Surgical Oncology >Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication
【24h】

Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication

机译:接受BRAF抑制剂治疗的患者转移切除术后的生存期与术前治疗时间和选择性适应证有关

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

IntroductionMetastasectomy can provide durable disease control for selected patients with metastatic melanoma. Vemurafenib is a BRAF kinase inhibitor which has demonstrated significant improvement in disease-specific survival in patients with metastatic melanoma with a BRAF gene mutation. This study examined the efficacy and safety of metastasectomy during treatment with vemurafenib.
机译:引言子宫切除术可以为部分转移性黑色素瘤患者提供持久的疾病控制。 Vemurafenib是一种BRAF激酶抑制剂,已证明具有BRAF基因突变的转移性黑色素瘤患者的疾病特异性生存率显着提高。这项研究检查了维罗非尼治疗期间转移切除术的有效性和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号